Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on February 20, 2003

Arteriosclerosis, Thrombosis, and Vascular Biology. 2003
Published online before print February 20, 2003, doi: 10.1161/01.ATV.0000062701.02853.AE
A more recent version of this article appeared on April 1, 2003
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/4/668    most recent
01.ATV.0000062701.02853.AEv1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Schonfeld, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Schonfeld, G.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Endothelium/vascular type/nitric oxide

Submitted on December 13, 2002
Accepted on February 4, 2003

Amino Terminal 38.9% of Apolipoprotein B-100 Is Sufficient to Support Cholesterol-Rich Lipoprotein Production and Atherosclerosis

Zhouji Chen *; Robin L. Fitzgerald ; Jeffrey E. Saffitz ; Clay F. Semenkovich ; and Gustav Schonfeld

From the Department of Medicine, Division of Atherosclerosis, Nutrition and Lipid Research (Z.C., R.L.F., C.F.S., G.S), and the Department of Pathology (J.E.S.), Washington University School of Medicine, St. Louis, Miss.

* To whom correspondence should be addressed. E-mail: zchen{at}im.wustl.edu.

Objective--Carboxyl terminal truncation of apolipoprotein (apo)B-100 and apoB-48 impairs their capacity for triglyceride transport, but the ability of the resultant truncated apoB to transport cholesterol and to support atherosclerosis has not been adequately studied. The atherogenicity of apoB-38.9 was determined in this study by using our apoB-38.9-only (Apob38.9/38.9) mice.

Methods and Results--ApoB-38.9-lipoproteins (Lp-B38.9) circulate at very low levels in Apob38.9/38.9 mice as small LDLs or HDLs. Disruption of apoE gene in these mice caused accumulation of large amounts of {beta}VLDL-like LpB-38.9 in plasma. These {beta}VLDL particles were more enriched with cholesteryl esters but poor in triglycerides compared with the apoB-48-{beta}VLDL of the apoB-wild-type/apoE-null (Apob+/+/Apoe-/-) mice. Likewise, apoB-38.9-VLDL secreted by cultured Apob38.9/38.9 mouse hepatocytes also had higher ratios of total cholesterol to triglycerides than apoB-48-VLDL secreted by the apoB-48-only hepatocytes. Thus, despite its impaired triglyceride-transporting capacity, apoB-38.9 has a relatively intact capacity for cholesterol transport. Spontaneous aortic atherosclerotic lesions were examined in apoB-38.9-only/apoE-null (Apob38.9/38.9 /Apoe-/-) mice at ages 9 and 13 months. Extensive lesions were found in the Apob38.9/38.9 /Apoe-/- mice as well as in their Apob38.9/38.9 /Apoe-/- and Apob+/+/Apoe-/- littermates.

Conclusion--Deleting the C-terminal 20% from apoB-48 does not impair its ability to transport cholesterol and to support atherosclerosis, thus narrowing the "atherogenic region" of apoB.


Key words: atherosclerosis • apolipoprotein B • animal model • VLDL secretion • cholesterol secretion • liver